Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan NEW
Price | Get Latest Price | |
Package | 5mg | 50mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-19 |
Product Details
Product Name: Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan | CAS No.: 2495742-34-0 |
Supply Ability: 10g | Release date: 2024/11/19 |
Product Introduction
Bioactivity
Name | Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan |
Description | Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is a conjugated compound used in the synthesis of antibody-drug conjugates (ADCs), featuring a topoisomerase inhibitor derivative linked via a linker to a specific ligand unit[1]. |
Storage | Shipping with blue ice. |
Inhibitors Related | Deruxtecan | Fmoc-Val-Cit-PAB-MMAE | Vc-MMAD | SMCC-DM1 | Mc-VC-PAB-SN38 | VCMMAE | CL2A-SN-38 | Val-Cit-PAB-MMAE | McMMAF | Mc-MMAE |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries, 10000+ Noval Small Molecucles,16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$98.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$98.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
$0.00/25mg |
VIP1Y
|
Xian confluore Biological Technology Co., Ltd.
|
2024-03-29 |
- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hills
INQUIRY